Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Boehringer Ingelheim
McKesson
Harvard Business School

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD2014

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for AZD2014?

AZD2014 is an investigational drug.

There have been 32 clinical trials for AZD2014. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and Cancer Research UK.

There are twenty-five US patents protecting this investigational drug and two hundred and sixty-seven international patents.

Recent Clinical Trials for AZD2014
TitleSponsorPhase
Vistusertib (AZD2014) For Recurrent Grade II-III MeningiomasAstraZenecaPhase 2
Vistusertib (AZD2014) For Recurrent Grade II-III MeningiomasNational Cancer Institute (NCI)Phase 2
Vistusertib (AZD2014) For Recurrent Grade II-III MeningiomasMassachusetts General HospitalPhase 2

See all AZD2014 clinical trials

Clinical Trial Summary for AZD2014

Top disease conditions for AZD2014
Top clinical trial sponsors for AZD2014

See all AZD2014 clinical trials

US Patents for AZD2014

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD2014   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
AZD2014   Start Trial Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors KuDOS Pharmaceuticals Limited (London, GB)   Start Trial
AZD2014   Start Trial Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN)   Start Trial
AZD2014   Start Trial CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD2014

Drugname Country Document Number Estimated Expiration Related US Patent
AZD2014 Australia 2014348657 2033-11-13   Start Trial
AZD2014 Australia 2017245411 2033-11-13   Start Trial
AZD2014 Canada 2929181 2033-11-13   Start Trial
AZD2014 China 105899232 2033-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKesson
Colorcon
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.